TrialCancer2017

Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial.

Yohann Loriot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.